<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04650256</url>
  </required_header>
  <id_info>
    <org_study_id>20200491</org_study_id>
    <nct_id>NCT04650256</nct_id>
  </id_info>
  <brief_title>Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences</brief_title>
  <official_title>Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VAUGHN-JORDAN FOUNDATION, INC.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to study a Chinese herbal Complementary and Alternative&#xD;
      Medicine (CAM) product for the temporary relief of pain and itching after radiotherapy (RT).&#xD;
      This is an over-the-counter product with 1% menthol as an active ingredient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients free of clinically relevant skin toxicities</measure>
    <time_frame>Up to 18 weeks.</time_frame>
    <description>Clinically relevant skin toxicities - Grade 2 with moist desquamation or Grade 3 or higher using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) as evaluated by the treating clinician.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SD-16 scores</measure>
    <time_frame>Up to 18 weeks.</time_frame>
    <description>Skindex 16 (SD-16) will be used to assess patients' self-assessment of skin effects. SD-16 has a total score ranging from 0-96 with a higher score indicating greater skin effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment of Cancer Therapy-Breast (FACT-B) scores</measure>
    <time_frame>Up to 18 weeks.</time_frame>
    <description>FACT-B in breast cancer patients will be used to obtain patient's self-assessment of health-related quality of life. FACT-B has a total score ranging from 0-148 with a higher score indicating a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-sensitivity C-reactive protein (hsCRP) values</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>The inflammatory biomarker, plasma high-sensitivity C-reactive protein (hsCRP) will be evaluated using blood samples.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Skin Toxicity</condition>
  <arm_group>
    <arm_group_label>CAM arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given the CAM intervention during scheduled, standard of care radiotherapy (up to 6 weeks) and 8-12 weeks (weeks 14-18) after radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Complementary and alternative medicine (CAM)</intervention_name>
    <description>CAM will be applied topically on the chest wall once during the day (or immediately after radiotherapy) and once at night daily.</description>
    <arm_group_label>CAM arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female subjects with newly diagnosed breast carcinoma&#xD;
&#xD;
          -  &gt; 18 years of age&#xD;
&#xD;
          -  Post-mastectomy with or without reconstruction&#xD;
&#xD;
          -  Stage II-IIIb with any receptor status&#xD;
&#xD;
          -  All races and ethnicities are eligible&#xD;
&#xD;
          -  Patients must be able to consent in English or Spanish&#xD;
&#xD;
          -  Plan to receive adjuvant radiotherapy to the chest wall +/- regional lymph nodes&#xD;
&#xD;
          -  RT will involve standard fractionation use of 3D conformal or Intensity-modulated RT&#xD;
             (IMRT)&#xD;
&#xD;
          -  Willing to sign protocol consent form&#xD;
&#xD;
          -  Patients are allowed to receive adjuvant hormonal therapy and/or targeted therapies&#xD;
             such as trastuzumab prior to, during and/or after radiation therapy.&#xD;
&#xD;
          -  Patients may receive chemotherapy before or after radiation therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior radiation to the involved breast or chest wall&#xD;
&#xD;
          -  Concurrent chemotherapy&#xD;
&#xD;
          -  Unable or unwilling to sign informed consent&#xD;
&#xD;
          -  Unable to speak English or Spanish&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Clinical or pathologic stage T4&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Connective tissue disorder including Systemic Lupus Erythematosus and Scleroderma&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer J Hu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U. of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer J Hu, PhD</last_name>
    <phone>3052437796</phone>
    <email>jhu@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer J Hu, PhD</last_name>
      <phone>305-243-7796</phone>
      <email>jhu@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer J Hu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2020</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Jennifer Hu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Complementary and alternative medicine</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

